These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 35092316)
1. Transparency of high-dimensional propensity score analyses: Guidance for diagnostics and reporting. Tazare J; Wyss R; Franklin JM; Smeeth L; Evans SJW; Wang SV; Schneeweiss S; Douglas IJ; Gagne JJ; Williamson EJ Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):411-423. PubMed ID: 35092316 [TBL] [Abstract][Full Text] [Related]
2. High-dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reporting. Rassen JA; Blin P; Kloss S; Neugebauer RS; Platt RW; Pottegård A; Schneeweiss S; Toh S Pharmacoepidemiol Drug Saf; 2023 Feb; 32(2):93-106. PubMed ID: 36349471 [TBL] [Abstract][Full Text] [Related]
3. Combining Super Learner with high-dimensional propensity score to improve confounding adjustment: A real-world application in chronic lymphocytic leukemia. Dhopeshwarkar N; Yang W; Hennessy S; Rhodes JM; Cuker A; Leonard CE Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5678. PubMed ID: 37609668 [TBL] [Abstract][Full Text] [Related]
4. A methodological review of the high-dimensional propensity score in comparative-effectiveness and safety-of-interventions research finds incomplete reporting relative to algorithm development and robustness. Martin GL; Petri C; Rozenberg J; Simon N; Hajage D; Kirchgesner J; Tubach F; Létinier L; Dechartres A J Clin Epidemiol; 2024 May; 169():111305. PubMed ID: 38417583 [TBL] [Abstract][Full Text] [Related]
5. Estimation of high-dimensional propensity scores with multiple exposure levels. Eberg M; Platt RW; Reynier P; Filion KB Pharmacoepidemiol Drug Saf; 2020 Jan; 29 Suppl 1():53-60. PubMed ID: 31571347 [TBL] [Abstract][Full Text] [Related]
6. Application of High-Dimensional Propensity Score Methods to the National Health and Aging Trends Study. Hamedani AG; Pham Nguyen TP; Willis AW; Tazare JR J Gerontol A Biol Sci Med Sci; 2024 Sep; 79(9):. PubMed ID: 39022830 [TBL] [Abstract][Full Text] [Related]
7. Evaluating the Performance of High-Dimensional Propensity Scores Compared with Standard Propensity Scores for Comparing Antihypertensive Therapies in the CPRD GOLD Database. Simon V; Vadel J Cardiol Ther; 2023 Jun; 12(2):393-408. PubMed ID: 37145352 [TBL] [Abstract][Full Text] [Related]
8. A comparison of confounder selection and adjustment methods for estimating causal effects using large healthcare databases. Benasseur I; Talbot D; Durand M; Holbrook A; Matteau A; Potter BJ; Renoux C; Schnitzer ME; Tarride JÉ; Guertin JR Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):424-433. PubMed ID: 34953160 [TBL] [Abstract][Full Text] [Related]
9. High-dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions. Neugebauer R; Schmittdiel JA; Zhu Z; Rassen JA; Seeger JD; Schneeweiss S Stat Med; 2015 Feb; 34(5):753-81. PubMed ID: 25488047 [TBL] [Abstract][Full Text] [Related]
10. Comparing the high-dimensional propensity score for use with administrative data with propensity scores derived from high-quality clinical data. Austin PC; Wu CF; Lee DS; Tu JV Stat Methods Med Res; 2020 Feb; 29(2):568-588. PubMed ID: 30975044 [TBL] [Abstract][Full Text] [Related]
11. Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. Toh S; García Rodríguez LA; Hernán MA Pharmacoepidemiol Drug Saf; 2011 Aug; 20(8):849-57. PubMed ID: 21717528 [TBL] [Abstract][Full Text] [Related]
12. Performance of the high-dimensional propensity score in adjusting for unmeasured confounders. Guertin JR; Rahme E; LeLorier J Eur J Clin Pharmacol; 2016 Dec; 72(12):1497-1505. PubMed ID: 27578249 [TBL] [Abstract][Full Text] [Related]
13. Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment. Polinski JM; Schneeweiss S; Glynn RJ; Lii J; Rassen JA Pharmacoepidemiol Drug Saf; 2012 May; 21 Suppl 2(Suppl 2):90-8. PubMed ID: 22552984 [TBL] [Abstract][Full Text] [Related]
14. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Schneeweiss S; Rassen JA; Glynn RJ; Avorn J; Mogun H; Brookhart MA Epidemiology; 2009 Jul; 20(4):512-22. PubMed ID: 19487948 [TBL] [Abstract][Full Text] [Related]
15. On the role of marginal confounder prevalence - implications for the high-dimensional propensity score algorithm. Schuster T; Pang M; Platt RW Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):1004-7. PubMed ID: 25866189 [TBL] [Abstract][Full Text] [Related]
16. Performance of the High-dimensional Propensity Score in a Nordic Healthcare Model. Hallas J; Pottegård A Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):312-317. PubMed ID: 27889951 [TBL] [Abstract][Full Text] [Related]
17. Machine learning for improving high-dimensional proxy confounder adjustment in healthcare database studies: An overview of the current literature. Wyss R; Yanover C; El-Hay T; Bennett D; Platt RW; Zullo AR; Sari G; Wen X; Ye Y; Yuan H; Gokhale M; Patorno E; Lin KJ Pharmacoepidemiol Drug Saf; 2022 Sep; 31(9):932-943. PubMed ID: 35729705 [TBL] [Abstract][Full Text] [Related]
18. Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments. Patorno E; Glynn RJ; Hernández-Díaz S; Liu J; Schneeweiss S Epidemiology; 2014 Mar; 25(2):268-78. PubMed ID: 24487209 [TBL] [Abstract][Full Text] [Related]
19. Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. Schneeweiss S; Eddings W; Glynn RJ; Patorno E; Rassen J; Franklin JM Epidemiology; 2017 Mar; 28(2):237-248. PubMed ID: 27779497 [TBL] [Abstract][Full Text] [Related]